Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Szukaj Study Connect
  • NCT05255601

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma - CA224-069

Zaktualizowano: 16 grudzień, 2024   |   ClinicalTrials.gov

Wydruk podsumowania

BIERZESZ POD UWAGĘ TO BADANIE?
Wydrukuj tę stronę i przewodnik po badaniu, aby pomóc sobie w rozmowie z lekarzem.
Skorzystaj z Przewodnika po badaniu, aby dowiedzieć się o procesie badań klinicznych. Zapoznaj się z kluczowymi czynnikami, które należy wziąć pod uwagę przed podjęciem decyzji i zanotuj pytania, aby zadać je personelowi medycznemu.
Wydrukuj tę stronę CA224-069
Pobierz przewodnik

WYBIERZ JĘZYK

Szczegóły badania

  • Phase 1/Phase 2

    Etap

  • Płeć

  • 0-30

    Zakres wieku

  • 38

    Lokalizacje

  • Recruiting

Opcje leczenia

Grupy badania
PRZYPISANA INTERWENCJA
Experimental: Relatlimab + Nivolumab
Drug: Relatlimab, Nivolumab

Kluczowe kryteria kwalifikacyjne

Inclusion Criteria: - Pathologically confirmed high-risk recurrent/relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), after non-response to or failure of first-line standard therapy prior to high-dose chemotherapy/autologous stem cell transplant (HDCT/ASCT) - Pathologically confirmed high-risk, R/R non-Hodgkin lymphoma (NHL) after failure or non-response to first-line therapy, including but not limited to diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL) and primary mediastinal B-cell lymphoma - Pathologically confirmed recurrent cHL or NHL - Must have measurable [18F]fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PET-CT) positive disease in both cHL and NHL cohorts Exclusion Criteria: - Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies - Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents - Prior autologous stem cell transplantation (HDCT/ASCT) - History of allogeneic bone marrow transplantation and with active graft versus host disease (GVHD) and prior history of Grade > 2 GVHD Other protocol-defined inclusion/exclusion criteria apply